Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-François Rossi

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemiaJean-François Rossi
Biomed Research International|October 2, 2015
Targeted Therapies in Adult B-Cell MalignanciesJean-François Rossi
Medecine Sciences : M/S|December 29, 2009
[Therapeutic monoclonal antibodies in onco-hematology]Guillaume Cartron, Jean-François Rossi
La Revue Du Praticien|March 13, 2010
[Monoclonal antibody therapy for non-Hodgkin's lymphoma]Franciane Paul, Jean-François Rossi, Guillaume Cartron
Cancer Communications (London, England)|June 16, 2019
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cellsJean-François Rossi, Patrice Céballos, Zhao-Yang Lu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidenceMohit Trikha, Robert Corringham, Bernard Klein, et al.
British Journal of Haematology|May 23, 2012
Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysisSophie Auger, Yohan Duny, Jean François Rossi, et al.
Cancer Biology & Medicine|February 6, 2024
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancerJean-François Rossi, Patrick Frayssinet, Maksim Matciyak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Interleukin-6 as a therapeutic targetJean-François Rossi, Zhao-Yang Lu, Michel Jourdan, et al.
Frontiers in Immunology|March 12, 2021
Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and CancerJean-François Rossi, Zhao Yang Lu, Cesare Massart, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemiaJean-François Rossi
Biomed Research International|October 2, 2015
Targeted Therapies in Adult B-Cell MalignanciesJean-François Rossi
Medecine Sciences : M/S|December 29, 2009
[Therapeutic monoclonal antibodies in onco-hematology]Guillaume Cartron, Jean-François Rossi
La Revue Du Praticien|March 13, 2010
[Monoclonal antibody therapy for non-Hodgkin's lymphoma]Franciane Paul, Jean-François Rossi, Guillaume Cartron
Cancer Communications (London, England)|June 16, 2019
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cellsJean-François Rossi, Patrice Céballos, Zhao-Yang Lu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidenceMohit Trikha, Robert Corringham, Bernard Klein, et al.
British Journal of Haematology|May 23, 2012
Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysisSophie Auger, Yohan Duny, Jean François Rossi, et al.
Cancer Biology & Medicine|February 6, 2024
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancerJean-François Rossi, Patrick Frayssinet, Maksim Matciyak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Interleukin-6 as a therapeutic targetJean-François Rossi, Zhao-Yang Lu, Michel Jourdan, et al.
Frontiers in Immunology|March 12, 2021
Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and CancerJean-François Rossi, Zhao Yang Lu, Cesare Massart, et al.
Pageof 7